Cargando…

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease

Background: CVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD). Previously, we reported that CVT-301 improved OFF symptoms relative to placebo. In this study, we evaluate pulmonary function in patients treated with a single...

Descripción completa

Detalles Bibliográficos
Autores principales:	LeWitt, Peter A., Pahwa, Rajesh, Sedkov, Alexander, Corbin, Ann, Batycky, Richard, Murck, Harald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994675/ https://www.ncbi.nlm.nih.gov/pubmed/29161531 http://dx.doi.org/10.1089/jamp.2016.1354

Ejemplares similares

The Clinical Development of Levodopa Inhalation Powder
por: Hauser, Robert A., et al.
Publicado: (2023)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease
por: Luinstra, Marianne, et al.
Publicado: (2019)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

CVT in the Peripartum Period: A Diagnostic Dilemma
por: Allbright, Leah, et al.
Publicado: (2020)

Apg9p/Cvt7p Is an Integral Membrane Protein Required for Transport Vesicle Formation in the Cvt and Autophagy Pathways
por: Noda, Takeshi, et al.
Publicado: (2000)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel, Ami B, et al.
Publicado: (2018)

Cerebral venous thrombosis (CVT) complicating tubercular meningitis
por: Li, Qian, et al.
Publicado: (2023)

Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease
por: Nutt, John G., et al.
Publicado: (2020)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Are corticosteroids useful in the treatment of brain edema associated with venous cerebral thrombosis (CVT) in patients with COVID-19 vaccine-related CVT? A controversial topic
por: Di Pietro, Martina, et al.
Publicado: (2022)

PNPLA6‐Related Disorder with Levodopa‐Responsive Parkinsonism
por: Kazanci, Serdar, et al.
Publicado: (2022)

CVT-Based Asynchronous BCI for Brain-Controlled Robot Navigation
por: Li, Mengfan, et al.
Publicado: (2023)

Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States
por: Amjad, Fahd, et al.
Publicado: (2019)

Norepinephrine: the next therapeutics frontier for Parkinson's disease
por: LeWitt, Peter A
Publicado: (2012)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Prediction of the Levodopa Challenge Test in Parkinson’s Disease Using Data from a Wrist-Worn Sensor
por: Khodakarami, Hamid, et al.
Publicado: (2019)

Quaternary structures of Vac8 differentially regulate the Cvt and PMN pathways
por: Park, Jumi, et al.
Publicado: (2019)

Implementing and Administering Cisco Solutions: 200-301 CCNA Exam Guide
por: Singh, Glen
Publicado: (2020)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
por: LeWitt, Peter A., et al.
Publicado: (2022)

Cvt9/Gsa9 Functions in Sequestering Selective Cytosolic Cargo Destined for the Vacuole
por: Kim, John, et al.
Publicado: (2001)

Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
por: Mueller, Karsten, et al.
Publicado: (2018)

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study
por: Poewe, Werner, et al.
Publicado: (2021)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017)

Neuroimaging of Cerebral Venous Thrombosis (CVT) – Old Dilemma and the New Diagnostic Methods
por: Walecki, Jerzy, et al.
Publicado: (2015)

Research on Clamping Force Control of CVT for Electric Vehicles Based on Slip Characteristics
por: Fu, Bing, et al.
Publicado: (2022)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
por: Svenningsson, Per, et al.
Publicado: (2018)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

Atypical Subacute Sclerosing Panencephalitis (SSPE): All Postpartum Altered Behavior Isn’t CVT!
por: Agarwal, Ayush, et al.
Publicado: (2021)

Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
por: Murck, Harald
Publicado: (2020)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
por: Marzinzik, Frank, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7epsd5gt9aadjspcoe75n3iu1n